
J&J agreed to acquire Ollin Biosciences for $2.2 billion upfront, and Lilly agreed to buy Calytrix Bio for up to $1.5 billion. Novartis licensed OBI Pharma’s ADC platform, and Seawolf debuted with $100 million and a Sanofi pact.
KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.
KBI will also continue to support other ongoing drug development programs for Merck from its two North Carolina facilities.
Source:






